AstraZeneca's novel asthma drug follows rivals into Phase III
This article was originally published in Scrip
Executive Summary
AstraZeneca has moved its anti-interleukin-13 product into Phase III testing as it plays catch up with Roche's similar product lebrikizumab in the increasingly competitive severe asthma area.